HALOPERIDOL DECANOATE

Post-LOE

haloperidol decanoate

Pfizer

ANDAINJECTIONINJECTABLE

Approved

Feb 2000

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

HALOPERIDOL DECANOATE (haloperidol decanoate) by Pfizer is unclear. Approved for schizophrenia in adults, schizophrenia. First approved in 2000.

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

unclear. However, its effect in schizophrenia could be mediated through its activity as an antagonist at central dopamine type 2 receptors. Haloperidol also binds to alpha-1 adrenergic receptors, but with lower affinity and displays minimal binding to muscarinic cholinergic and histaminergic (H1)…

Indications (2)

schizophrenia in adults schizophrenia

Worked on HALOPERIDOL DECANOATE at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.